Vasoactive intestinal peptide (VIP) is a real, naturally occurring 28-amino-acid human hormone found throughout the gut, lungs, brain and immune system, with a native plasma half-life of only one to two minutes. Its Western human trials, in COVID-19 acute respiratory distress syndrome and pulmonary arterial hypertension, all used either a synthetic copy delivered by continuous infusion or inhalation, or a chemically modified long-acting analogue built specifically to get around that short half-life, not periodic self-injection of the native peptide. No trial located for this entry tested that self-use pattern for general immune, sleep or inflammatory purposes.
Ask about VIP / aviptadil
Research snapshot
| Peptide category | Endogenous 28-amino-acid human neuropeptide hormone (native, plus synthetic/engineered drug analogues) |
| Primary research interest | COVID-19 acute respiratory distress syndrome (synthetic aviptadil) and pulmonary arterial hypertension (engineered pemziviptadil); native VIP also used in small mechanistic infusion studies |
| Highest available evidence | Published randomized, placebo-controlled human clinical trials, but of synthetic/engineered analogues, not periodic self-injection of native VIP |
| Human research available | Yes, for synthetic/engineered analogues and short mechanistic infusion studies; no trial of periodic self-injected native VIP for general immune or wellness use |
| Development status | Aviptadil and pemziviptadil have been through Phase 2/3-stage trials; results mixed, at least one trial terminated and one withdrawn before enrolling |
| Regulatory status | Not approved as a standalone drug in this form; engineered analogues studied under FDA-regulated trials, none completed to approval |
Technical identity
| Primary name | VIP (Vasoactive Intestinal Peptide) |
| Alternative names | Vasoactive intestinal polypeptide; Aviptadil (synthetic drug form); “VIP nasal spray” / “VIP peptide” (community names) |
| Peptide sequence | His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn |
| Amino-acid length | 28 residues |
| Molecular formula | Not independently re-verified in this research pass |
| Molecular weight | Approximately 3326 g/mol (native human VIP) |
| CAS Registry Number | Not independently re-verified in this research pass |
| PubChem CID | Not independently re-verified in this research pass |
| UNII | Not established |
| DrugBank ID | Not established |
| Chemical modifications | None in the native hormone; aviptadil is a synthetic copy of the native sequence, pemziviptadil (PB1046) is a chemically engineered sustained-release analogue |
| Peptide class | Endogenous neuropeptide hormone, secretin/glucagon peptide superfamily |
| Primary biological target | VIP receptors (VPAC1/VPAC2) across gut, lung, brain, and immune tissue |
| Developer or originator | Endogenous human hormone; aviptadil and pemziviptadil (PB1046) are pharmaceutical-industry drug candidates built from it |
| Development status | Native VIP: naturally occurring, not a drug candidate itself. Aviptadil and pemziviptadil: trialed, neither completed to approval |
What it is
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino-acid human neuropeptide hormone, produced throughout the gut, lungs, brain and immune system, with roles in smooth-muscle relaxation, vasodilation, secretion and immune signalling. Unlike most compounds on this site, VIP is not a novel research molecule; it is the same sequence as an endogenous human hormone, and synthetic copies or engineered analogues of it have been developed as actual drugs.
Its native plasma half-life is extremely short, on the order of one to two minutes, which has driven drug development toward either continuous infusion, inhalation, or chemically modified long-acting analogues rather than simple periodic injection of the native peptide.
Potential benefits and research applications
COVID-19 acute respiratory distress syndrome, tested with a synthetic analogue, not periodic self-injection
Aviptadil, a synthetic copy of the native VIP sequence, was studied intravenously and by inhalation for COVID-19-associated ARDS in randomized, placebo-controlled, double-blind multicenter trials. Results and trial fates were mixed, and at least one large inhaled trial was withdrawn before enrolling.
Evidence: has been reported in randomized, placebo-controlled human trials (Tier 1, published human clinical evidence) with mixed and incomplete results; not established as an effective treatment, and not tested as a periodic subcutaneous self-injection.
Pulmonary arterial hypertension, tested with an engineered long-acting analogue
Pemziviptadil (PB1046), a sustained-release engineered VIP analogue built for once-weekly dosing, was studied in a randomized, double-blind, placebo-controlled Phase 2 trial in pulmonary arterial hypertension. The trial was later terminated.
Evidence: has been reported in one randomized, placebo-controlled human trial (Tier 1) that did not reach completion; has not been established as effective, and the analogue tested is chemically distinct from native VIP.
General immune, inflammatory and wellness support, the claim with no matching trial design
VIP is frequently marketed and self-administered for general immune modulation, inflammatory conditions such as “mold illness,” sleep and wellness. No registered or published trial located for this entry tested periodic subcutaneous injection of native VIP for any of these purposes.
Evidence: has been reported anecdotally (Tier 6, community-reported information); has not been established by any clinical trial, and the native peptide’s one-to-two-minute half-life raises a specific, unaddressed question about whether an injected dose could produce any sustained effect at all.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| COVID-19 ARDS (inhaled aviptadil) | Inhalation | 67 mcg | Three times daily | 10 days (per trial protocol) | Published human clinical trial protocol (randomized, placebo-controlled) |
| Pulmonary arterial hypertension (pemziviptadil) | Subcutaneous | Engineered sustained-release dose, per trial protocol | Once weekly | Trial duration (terminated before completion) | Registered human clinical trial (Phase 2, terminated) |
| Migraine / headache mechanistic studies | Continuous IV infusion | Controlled infusion dose, per trial protocol | Single infusion session | Hours (infusion study) | Published human research (small mechanistic infusion study) |
| General immune/inflammatory/wellness use (native VIP) | Subcutaneous or intranasal | Commonly reported as 50 to 100 mcg per dose | Once or twice daily | Often cycled, weeks | Community / vendor reported: does not resemble the pharmacology of any studied regimen, and no trial has tested whether it does anything given native VIP’s 1-2 minute half-life |
The human trial record, and what it is actually testing
Aviptadil, a synthetic form of the same 28-amino-acid VIP sequence, has been studied intravenously and by inhalation for COVID-19-associated acute respiratory distress syndrome, in randomized, placebo-controlled, double-blind multicenter trials; results and trial fates were mixed, and at least one large inhaled-aviptadil COVID-19 trial (AVICOVID-3) was withdrawn before enrolling.
Pemziviptadil (PB1046), a sustained-release engineered VIP analogue built for once-weekly subcutaneous dosing rather than the native peptide’s minutes-long half-life, was studied in pulmonary arterial hypertension in a randomized, double-blind, placebo-controlled Phase 2 trial that was later terminated, and separately in a small open-label Phase 1 dose-titration study in the same population.
Native VIP itself, unmodified, has been given to small numbers of healthy volunteers and migraine patients by controlled infusion in mechanistic headache studies at Danish academic centers, and has been studied observationally in COPD-associated pulmonary hypertension. These are short-infusion physiology studies, not treatment trials, and none used a self-administered subcutaneous injection schedule.
No registered trial located for this entry tests periodic subcutaneous self-injection of native VIP for general immune, sleep, longevity or inflammatory purposes, which is how this compound is most often described in circulating research-peptide material.
What is not known
Whether a periodic subcutaneous injection of native VIP, a peptide with a one-to-two-minute plasma half-life, produces any sustained effect at all. The engineered analogues that were built specifically to get around that short half-life used different chemistry and different dosing schedules than a simple injection of the native sequence.
Whether native VIP has any established role in the general immune, inflammatory or “mold illness” protocols it is sometimes marketed for. No trial located for this entry tested that use.
Long-term safety of native VIP given repeatedly outside a hospital or research infusion setting.
Frequently asked questions
What is VIP?
Vasoactive intestinal peptide is a real, naturally occurring 28-amino-acid human hormone involved in smooth-muscle relaxation, vasodilation, secretion and immune signalling, with an extremely short native plasma half-life of one to two minutes.
How does VIP work?
It acts as a signalling hormone across the gut, lungs, brain and immune system through VIP receptors, producing smooth-muscle relaxation, vasodilation and secretory and immune effects. Its extremely short half-life is why drug developers have used continuous infusion, inhalation or chemically modified long-acting analogues rather than simple injection.
What dosage has been studied in humans?
Studied regimens include continuous IV infusion, inhaled aviptadil at 67 micrograms three times daily, and a once-weekly engineered long-acting analogue (pemziviptadil). No trial tested a periodic subcutaneous injection of native VIP.
What dosage commonly circulates online?
Circulating material describes native VIP at 50 to 100 micrograms, subcutaneously or intranasally, once or twice daily. This does not resemble the pharmacology of any studied regimen, and no trial has tested whether it does anything.
Has VIP been studied in humans?
Yes, but as synthetic copies or engineered analogues for specific medical conditions (COVID-19 ARDS, pulmonary arterial hypertension), and in small mechanistic infusion studies for migraine and COPD, not as a periodic self-injected general-use peptide.
Is VIP approved for use?
Not as a standalone drug in this form. Engineered analogues have been studied in FDA-regulated trials, but none has been completed to approval in the sources reviewed for this entry.
What routes of administration are reported?
Trials used continuous IV infusion or inhalation for the synthetic and engineered forms. Community-reported use of native VIP describes subcutaneous or intranasal administration.
Does VIP help with general immune or inflammatory conditions?
This has not been established. No trial located for this entry tested native VIP for general immune, inflammatory or “mold illness” use.
What side effects have been reported?
Reported effects vary by formulation and trial; a comprehensive side-effect profile for self-administered native VIP was not established in the sources reviewed for this entry.
What remains unknown about VIP?
Whether a periodic subcutaneous injection of the native, minutes-long-half-life peptide produces any sustained effect at all; whether it has any established role in general immune or inflammatory protocols; and its long-term safety outside a hospital or research infusion setting.
Bottom line
VIP is a real, well-characterized human hormone, but the gap between its studied pharmacology and how it circulates as a research peptide is unusually wide. Every Western human trial located for this entry used either continuous infusion, inhalation, or a chemically re-engineered long-acting analogue, specifically because native VIP disappears from the bloodstream within minutes. No trial has tested whether a periodic subcutaneous shot of the native peptide, the way it is actually used and sold, does anything at all.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Immune/inflammatory support, general | Subcutaneous or intranasal | 50 to 100 mcg per dose | Once or twice daily | Often cycled, weeks |
Circulating material describes native VIP at 50 to 100 micrograms, subcutaneously or intranasally, once or twice daily. The clinical trials located for this entry either used continuous IV infusion, thrice-daily inhalation of 67 micrograms (in the inhaled aviptadil COVID-19 protocol), or a chemically modified once-weekly analogue built specifically because the native peptide does not last between doses. A twice-daily subcutaneous shot of native VIP does not resemble the pharmacology of any of those studied regimens, and no trial has tested whether it does anything at all.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Boesing M, et al. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. Trials 2022;23(1):790. Human RCT protocol, 67 mcg inhaled 3x/day for 10 days. PMID 36127739
- PhaseBio Pharmaceuticals. Phase 2 randomized, double-blind, placebo-controlled trial of pemziviptadil (PB1046), a sustained-release VIP analogue, in pulmonary arterial hypertension. Terminated. NCT03556020
- Danish Headache Center. Effects of a long-lasting infusion of native VIP on headache, cranial hemodynamics and autonomic symptoms in episodic migraine without aura. Human, controlled IV infusion, mechanistic study. NCT04260035
Compare VIP with related compounds
Research area: Neuro and cognitive.